TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Breast Cancer Incidence Reduced 45% In Tamoxifen Arm Of BCPT; Trial Unblinded April 10, 1998